Tocilizumab [375823-41-9]
Référence HY-P9917-1mg
Conditionnement : 1mg
Marque : MedChemExpress
Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
CAS No. : 375823-41-9
This product is a controlled substance and not for sale in your territory.
Based on 23 publication(s) in Google Scholar
Voir tous les produits spécifiques à Isoform Interleukin Related:
Description |
Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis[1]. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease)[4]. |
||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Isotype |
Human IgG1 kappa |
||||||||||||||||||||||||||||||||
Recommend Isotype Controls |
Human IgG1 kappa, Isotype Control |
||||||||||||||||||||||||||||||||
Species |
Humanized |
||||||||||||||||||||||||||||||||
IC50 & Target[1][2] |
|
||||||||||||||||||||||||||||||||
In Vitro |
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1-100 ng/mL; 24 hours, 48 hours) inhibits the cell proliferation (growth rate) in a dose-dependent manner, growth rate by HACM is reduced almost completely by 100 ng/mL tocilizumab[2]. Tocilizumab (Anti-Human IL6R, Humanized Antibody) (0.001-10,000 μg/ml; 2 days) inhibits Ba/F3-gp130-IL-6R cell proliferation stimulated with hIL-6 with an IC50 of 13.5 ng/ml[1]. Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1 μM; 6 hours) reduces the phosphorylation of STAT3 in vitro consistent with in vivo SAS cells[3]. Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1-5 μM; 24 hours) significantly reduces VEGF mRNA expression in SAS cells with serum-free medium[3]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay[2]
Cell Cytotoxicity Assay[1]
Western Blot Analysis[3]
RT-PCR[3]
|
||||||||||||||||||||||||||||||||
In Vivo |
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intravenous injection; 1.0 mg/100 μL; twice a week, three weeks) decreases the volume of each metastatic focus in tocilizumab-injected mouse brains[2]. Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intraperitoneal injection;100 μg/mL, every 48 hours; 20days) suppresses OSCC progression and suppresses Tumor Angiogenesis[3]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
|
||||||||||||||||||||||||||||||||
Essai clinique |
|
||||||||||||||||||||||||||||||||
CAS No. |
375823-41-9 |
||||||||||||||||||||||||||||||||
Appearance |
Liquid |
||||||||||||||||||||||||||||||||
Color |
Colorless to light yellow |
||||||||||||||||||||||||||||||||
SMILES |
[Tocilizumab] |
||||||||||||||||||||||||||||||||
Livraison | Shipping with dry ice. |
||||||||||||||||||||||||||||||||
Stockage |
Please store the product under the recommended conditions in the Certificate of Analysis. |
||||||||||||||||||||||||||||||||
Format |
|
||||||||||||||||||||||||||||||||
Biological Activity |
|
||||||||||||||||||||||||||||||||
Pureté et documentation | |||||||||||||||||||||||||||||||||
Références |
|
Tocilizumab Related Classifications
- Inflammation/Immunology Cancer
- Cancer Targeted Therapy Cancer Immunotherapy
- Inhibitory Antibodies
- Immunology/Inflammation
- Interleukin Related